Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (2): 143-150.doi: 10.6040/j.issn.1673-3770.0.2022.016

• 综述 • Previous Articles     Next Articles

Advances in immune vaccines for head and neck squamous cell carcinoma

AI Ziqin1,2, LI Junzheng1,2,3   

  1. 1. Clinical Medical College of Guizhou Medical University, Guiyang 550004, Guizhou, China;
    2. Department of Otorhinolaryngology & Head and Neck Surgery, Guangzhou Red Cross Hospital Affiliated to Jinan University, Guangzhou 510220, Guangdong, China;
    3. Department of Otorhinolaryngology & Head and Neck Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong, China
  • Published:2023-03-30

PDF (PC)

318

Abstract: Head and neck squamous cell carcinoma is the most common pathological type of the head and neck tumor, and its incidence is increasing annually. Most cases are discovered only in the middle and late stages, when prognosis is poor and mortality rate is high. With increasing research, the treatment mechanism is becoming clearer and the available therapies are more diverse. Immune vaccines, as an emerging immunotherapy modality, are gradually becoming one of the hot topics in the treatment of head and neck squamous cell carcinoma because of their unique advantages. It is divided into preventive vaccine and therapeutic vaccine, which are effective on the treatment of head and neck squamous cell carcinoma by different mechanisms. Compared with other immunotherapy methods, immune vaccine can treat more accurately with mild side effects. As the immune vaccine moves toward individualized customization, it is expected to become a powerful tool for anticancer immunotherapy. We reviewed and summarized the progress of immune vaccines in head and neck squamous cell carcinoma research, and discussed its future development prospects.

Key words: Head and neck squamous cell carcinoma, Immunotherapy, Immune vaccine, Preventive vaccine, Therapeutic vaccine

CLC Number: 

  • R739.91
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi:10.3322/caac.21660
[2] Fitzmaurice C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: a systematic analysis for the Global Burden of Disease study[J]. J Clin Oncol, 2018, 36(15_suppl): 1568. doi:10.1200/jco.2018.36.15_suppl.1568
[3] Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis[J]. Oncologist, 2010, 15(9): 994-1001. doi:10.1634/theoncologist.2009-0289
[4] Cohen N, Fedewa S, Chen AY. Epidemiology and demographics of the head and neck cancer population[J]. Oral Maxillofac Surg Clin North Am, 2018, 30(4): 381-395. doi:10.1016/j.coms.2018.06.001
[5] Liu WL, Qdaisat A, Zhou SH, et al. Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers[J]. Head Neck, 2021, 43(2): 613-621. doi:10.1002/hed.26510
[6] Gau M, Karabajakian A, Reverdy T, et al. Induction chemotherapy in head and neck cancers: results and controversies[J]. Oral Oncol, 2019, 95: 164-169. doi:10.1016/j.oraloncology.2019.06.015
[7] Baudelet M, van den Steen L, Tomassen P, et al. Very late xerostomia, dysphagia, and neck fibrosis after head and neck radiotherapy[J]. Head Neck, 2019, 41(10): 3594-3603. doi:10.1002/hed.25880
[8] Coley WB. Ⅱ. contribution to the knowledge of sarcoma[J]. Ann Surg, 1891, 14(3): 199-220. doi:10.1097/00000658-189112000-00015
[9] Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. doi:10.6004/jnccn.2020.0012
[10] Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62. doi:10.1038/nrclinonc.2017.148
[11] Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020, 70(2): 86-104. doi:10.3322/caac.21596
[12] Gavrielatou N, Doumas S, Economopoulou P, et al. Biomarkers for immunotherapy response in head and neck cancer[J]. Cancer Treat Rev, 2020, 84: 101977. doi:10.1016/j.ctrv.2020.101977
[13] O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3): 151-167. doi:10.1038/s41571-018-0142-8
[14] Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer[J]. Nat Rev Cancer, 2018, 18(5): 269-282. doi:10.1038/nrc.2018.11
[15] Pauken KE, Lagattuta KA, Lu BY, et al. TCR-sequencing in cancer and autoimmunity: barcodes and beyond[J]. Trends Immunol, 2022, 43(3): 180-194. doi:10.1016/j.it.2022.01.002
[16] Zhu YT, Liu JY. The role of neoantigens in cancer immunotherapy[J]. Front Oncol, 2021, 11: 682325. doi:10.3389/fonc.2021.682325
[17] Chen YP, Wang YQ, Lv JW, et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy[J]. Ann Oncol, 2019, 30(1): 68-75. doi:10.1093/annonc/mdy470
[18] Seliger B, Massa C, Yang B, et al. Immune escape mechanisms and their clinical relevance in head and neck squamous cell carcinoma[J]. Int J Mol Sci, 2020, 21(19): 7032. doi:10.3390/ijms21197032
[19] Lee MY, Allen CT. Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer[J]. Head Neck, 2020, 42(9): 2722-2733. doi:10.1002/hed.26158
[20] Zhang XH, Shi MQ, Chen TL, et al. Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy[J]. Mol Ther Nucleic Acids, 2020, 22: 298-309. doi:10.1016/j.omtn.2020.08.030
[21] Yao Y, Chen CL, Yu D, et al. Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy[J]. Allergy, 2021, 76(2): 456-470. doi:10.1111/all.14639
[22] Brooks JM, Menezes AN, Ibrahim M, et al. Development and validation of a combined hypoxia and immune prognostic classifier for head and neck cancer[J]. Clin Cancer Res, 2019, 25(17): 5315-5328. doi:10.1158/1078-0432.CCR-18-3314
[23] Takahashi H, Sakakura K, Ida S, et al. Circulating naïve and effector memory T cells correlate with prognosis in head and neck squamous cell carcinoma[J]. Cancer Sci, 2022, 113(1): 53-64. doi:10.1111/cas.15195
[24] Albers AE, Qian X, Kaufmann AM, et al. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer[J]. Sci Rep, 2018, 8(1): 10716. doi:10.1038/s41598-018-29067-5
[25] Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy[J]. J Immunol Res, 2020: 5825401. doi:10.1155/2020/5825401
[26] Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments[J]. Nat Rev Immunol, 2021, 21(2): 83-100. doi:10.1038/s41577-020-00479-7
[27] Garbuglia AR, Lapa D, Sias C, et al. The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease[J]. Front Immunol, 2020, 11: 188. doi:10.3389/fimmu.2020.00188
[28] Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev, 2020, 33(2): e00046-e00019. doi:10.1128/CMR.00046-19
[29] Diana G, Corica C. Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence? [J]. Oral Oncol, 2021, 115: 105168. doi:10.1016/j.oraloncology.2020.105168
[30] Roman BR, Aragones A. Epidemiology and incidence of HPV-related cancers of the head and neck[J]. J Surg Oncol, 2021, 124(6): 920-922. doi:10.1002/jso.26687
[31] Giuliano AR, Wilkin T, Bautista OM, et al. Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men[J]. Contemp Clin Trials, 2022, 115: 106592. doi:10.1016/j.cct.2021.106592
[32] Morse MA, Gwin WR 3rd, Mitchell DA. Vaccine therapies for cancer: then and now[J]. Target Oncol, 2021, 16(2): 121-152. doi:10.1007/s11523-020-00788-w
[33] Stern PL. Key steps in vaccine development[J]. Ann Allergy Asthma Immunol, 2020, 125(1): 17-27. doi:10.1016/j.anai.2020.01.025
[34] Saxena M, van der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378. doi:10.1038/s41568-021-00346-0
[35] Tran T, Blanc C, Granier C, et al. Therapeutic cancer vaccine: building the future from lessons of the past[J]. Semin Immunopathol, 2019, 41(1): 69-85. doi:10.1007/s00281-018-0691-z
[36] Julian R, Savani M, Bauman JE. Immunotherapy approaches in HPV-associated head and neck cancer[J]. Cancers, 2021, 13(23): 5889. doi:10.3390/cancers13235889
[37] Lechner M, Liu J, Masterson L, et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management[J]. Nat Rev Clin Oncol, 2022, 19(5): 306-327. doi:10.1038/s41571-022-00603-7
[38] Wang RJ, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge[J]. Cancer Lett, 2020, 471: 88-102. doi:10.1016/j.canlet.2019.11.039
[39] Shibata H, Zhou LY, Xu N, et al. Personalized cancer vaccination in head and neck cancer[J]. Cancer Sci, 2021, 112(3): 978-988. doi:10.1111/cas.14784
[40] Stephens AJ, Burgess-Brown NA, Jiang SS. Beyond just peptide antigens: the complex world of peptide-based cancer vaccines[J]. Front Immunol, 2021, 12: 696791. doi:10.3389/fimmu.2021.696791
[41] Nelde A, Rammensee HG, Walz JS. The peptide vaccine of the future[J]. Mol Cell Proteomics, 2021, 20: 100022. doi:10.1074/mcp.R120.002309
[42] Gaglione R, Pane K, Dell'Olmo E, et al. Cost-effective production of recombinant peptides in Escherichia coli[J]. N Biotechnol, 2019, 51: 39-48. doi:10.1016/j.nbt.2019.02.004
[43] Li M, Josephs RD, Daireaux A, et al. Structurally related peptide impurity identification and accurate quantification for synthetic oxytocin by liquid chromatography-high-resolution mass spectrometry[J]. Anal Bioanal Chem, 2021, 413(7): 1861-1870. doi:10.1007/s00216-021-03154-5.
[44] Li WY, Separovic F, O'brien-Simpson NM, et al. Chemically modified and conjugated antimicrobial peptides against superbugs[J]. Chem Soc Rev, 2021, 50(8): 4932-4973. doi:10.1039/d0cs01026j.
[45] Wanning S, Süverkrüp R, Lamprecht A. Impact of excipient choice on the aerodynamic performance of inhalable spray-freeze-dried powders[J]. Int J Pharm, 2020, 586: 119564. doi:10.1016/j.ijpharm.2020.119564.
[46] Bowen WS, Svrivastava AK, Batra L, et al. Current challenges for cancer vaccine adjuvant development[J]. Expert Rev Vaccines, 2018, 17(3): 207-215. doi:10.1080/14760584.2018.1434000.
[47] Gouttefangeas C, Rammensee HG. Personalized cancer vaccines: adjuvants are important, too[J]. Cancer Immunol Immunother, 2018, 67(12): 1911-1918. doi:10.1007/s00262-018-2158-4.
[48] Chen XT, Yang J, Wang LF, et al. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives[J]. Theranostics, 2020, 10(13): 6011-6023. doi:10.7150/thno.38742.
[49] Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J]. Nat Rev Clin Oncol, 2021, 18(4): 215-229. doi:10.1038/s41571-020-00460-2.
[50] Fries CN, Curvino EJ, Chen JL, et al. Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health[J]. Nat Nanotechnol, 2021, 16(4): 1-14. doi:10.1038/s41565-020-0739-9.
[51] Isidro-Llobet A, Kenworthy MN, Mukherjee S, et al. Sustainability challenges in peptide synthesis and purification: from R&D to production[J]. J Org Chem, 2019, 84(8): 4615-4628. doi:10.1021/acs.joc.8b03001.
[52] Yoshitake Y, Fukuma D, Yuno A, et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS[J]. Clin Cancer Res, 2015, 21(2): 312-321. doi:10.1158/1078-0432.CCR-14-0202.
[53] Yang MC, Yang A, Qiu J, et al. Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant[J]. Cell Biosci, 2016, 6: 17. doi:10.1186/s13578-016-0083-9.
[54] Ogasawara M, Miyashita M, Yamagishi Y, et al. Phase Ⅰ/Ⅱ pilot study of wilms' tumor 1 peptide-pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer[J]. Ther Apher Dial, 2019, 23(3): 279-288. doi:10.1111/1744-9987.12831.
[55] Hobernik D, Bros M. DNA vaccines-how far from clinical use? [J]. Int J Mol Sci, 2018, 19(11): 3605. doi:10.3390/ijms19113605.
[56] Song Q, Zhang CD, Wu XH. Therapeutic cancer vaccines: from initial findings to prospects[J]. Immunol Lett, 2018, 196: 11-21. doi:10.1016/j.imlet.2018.01.011.
[57] Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies[J]. Vaccines, 2019, 7(2): 37. doi:10.3390/vaccines7020037.
[58] Wen R, Umeano AC, Kou Y, et al. Nanoparticle systems for cancer vaccine[J]. Nanomedicine(Lond), 2019, 14(5): 627-648. doi:10.2217/nnm-2018-0147.
[59] Chai SJ, Fong SCY, Gan CP, et al. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients[J]. Hum Vaccin Immunother, 2019, 15(1): 167-178. doi:10.1080/21645515.2018.1520584.
[60] Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor[J]. Curr Cancer Drug Targets, 2007, 7(7): 633-642. doi:10.2174/156800907782418310.
[1] LIU Jiahui, TIAN Ruxian, LI Yumei, SONG Xicheng. Construct of a cuproptosis-related lncRNA model to predict prognosis in head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(2): 49-64.
[2] GU Min, LU Meiping. Advances in the application of nanomedicine delivery systems in allergen immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 106-111.
[3] PAN Linlin, WAN Jiaming, LI Yue, HE Long. Autophagy-related long noncoding RNA is a prognostic indicator for head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 97-107.
[4] XU Xuemeng, FAN Lei, YU Wangbo, JIANG Zhiyue, PAN Chen, HUANG Yongqin. Meta-analysis of the efficacy of omalizumab in combination with specific immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 26-33.
[5] ZHANG Ting, WANG Meilan, GAO Yingqin. Research progress of IL-35 in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 139-147.
[6] YANG Ming, LIU Xuexia, ZHANG Hua. Progress of m6A recognition protein IGF2BPs in head and neck cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 153-161.
[7] XIE Yulin, LEI Dapeng. Advances in the pathological study of artificial intelligence in the lymph node metastasis of head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(3): 124-129.
[8] SONG Fei, SONG Hao, LI Yumei, MOU Yakui, SONG Xicheng. Immunomodulatory roles of tumor-derived exosomes in the microenvironment of head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(1): 92-100.
[9] ZHOU Yijing, ZOU Jianyin, YI Hongliang, WU Hongmin. Expression of TGFBI in head and neck squamous cell carcinoma and its clinical significance [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 85-95.
[10] TU Qiaoling, LI Yufeng, PENG Jun. Advances in anti-PD-L1/PD-1 therapy and non-coding RNA regulation in nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 135-141.
[11] YANG Yingling, GOU Haocheng, FENG Jun. Review of pyroptosis molecular mechanism and applications in head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 160-165.
[12] SUO Anqi, YANG Xinxin. Research progress on the relationship between mitochondrial autophagy and squamous cell carcinoma of the head and neck [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 111-117.
[13] PANG Chong, BIAN Sainan, ZHANG Bing, YIN Xu, LU Yingxia, YE Pengfei, WANG Zhan, ZHAO Jing, GAO Yan, GUAN Kai. Short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 70-74.
[14] LI Menghui, ZHI Lili, QI Kaiwen, WANG Shanshan, GAO Qian, BU Meiling,. Clinical research of subcutaneous immunotherapy on children with allergic asthma caused by dust mites and combined with mold allergen [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 75-80.
[15] WEI Ya'nan,CHEN Xi. Progress in chemotherapy and targeted drug therapy for locally advanced head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 118-124.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd